Jazz Pharmaceuticals plc ended a nearly seven-year spat over its blockbuster narcolepsy treatment, Xyrem (sodium oxybate), by granting Hikma Pharmaceuticals plc the right to sell an authorized generic version of the drug under its new drug application (NDA) in the U.S., beginning Jan. 1, 2023.